免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展

doi:10.11904/j.issn.1002-3070.2020.03.015

摘要/Abstract

摘要： 卵巢癌是欧洲和美国女性中最致命的妇科恶性肿瘤,发病机制复杂、易复发,给予积极治疗预后仍较差。目前免疫疗法成为继传统疗法后又一新型抗肿瘤疗法,其中程序性细胞死亡受体-1(PD-1)/程序性细胞死亡配体-1(PD-L1)抑制剂在包括黑色素瘤、非小细胞肺癌等在内的多种恶性肿瘤治疗中取得显著疗效,但其在卵巢癌的临床治疗中的效果有待研究。本文就PD-1/PD-L1免疫抑制剂在卵巢癌的治疗进展及副反应处理方面进行综述,探讨免疫抑制剂应用于卵巢癌的可行性。

关键词: 卵巢癌, 程序性死亡受体-1/程序性死亡配体-1抑制剂, 免疫治疗, 免疫抑制剂

Abstract: Ovarian cancer is the most deadly gynecological malignancy in women from European and the United States.Its pathogenesis is complex pathogenesis and easy to recurrence.The prognosis is still poor after active treatment.At present,immunotherapy has become a new type of anti-tumor therapy after traditional therapies,in which programmed cell death receptor-1(PD-1)/programmed cell death ligand-1(PD-L1)inhibitors have shown remarkable efficacy in the treatment of various malignant tumors including melanoma and non-small cell lung cancer,and other malignant tumors.However,their effects on the clinical treatment of ovarian cancer need to be studied.This article summarizes the progress of PD-1/PD-L1 immunosuppressive agents in ovarian cancer and the treatment of side effects,and explores the feasibility of applying immunosuppressive agents to ovarian cancer,which brings hope for the treatment of ovarian cancer.

Key words: Ovarian cancer, Programmed cell death-1/programmed cell death ligand-1 inhibitors, Immunotherapy, Immunity inhibitor

中图分类号:

R737.31

侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.

HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer[J]. Journal of Practical Oncology, 2020, 34(3): 266-270.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.03.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I3/266

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
2 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
3 Cortez AJ,Tudrej P,Kujawa KA,et al.Advances in ovarian cancer therapy[J].Cancer Chemother Pharmacol,2018,81(1):17-38.
4 Reid BM,Permuth JB,Sellers TA.Epidemiology of ovarian cancer:a review[J].Cancer Biol Med,2017,14(1):9-32.
5 Bozas G,Terpos E,Gika D,et al.Prechemotherapy serum levels of CD105,transforming growth factor beta2,and scular endothelial growth factor are associated with prognosis in patients with dvanced epithelial ovarian cancer treated with cytoreductive surgery andplatinum-based emotherapy[J].Int J Gynecol Cancer,2010,20(2):248-254.
6 Kleffel S,Posch C,Barthel SR,et al.Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth[J].Cell,2015,162(6):1242-1256.
7 张智,张一琼.Foxp3+Tregs及PD1在上皮性卵巢癌组织中的表达及其临床病理意义[J].南昌大学学报(医学版),2018,58(5):54-58.
8 Tan D,Sheng L,Yi QH.Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer[J].Cancer Biomark,2018,21(2):287-297.
9 韩滕,唐丽萍.PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J].实用肿瘤学杂志,2018,32(5):468-470.
10 Zou W,Chen L.Inhibitory B7 family molecules in the tumour microenvironment[J].Nat Rev Immunol,2008,8(6):467-477.
11 Hamanishi J,Mandai M,Iwasaki M,et al.Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer[J].Proc Natl Acad Sci U S A,2007,104(9):3360-3365.
12 Abiko K,Mandai M,Hamanishi J,et al.PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction[J].Clin Cancer Res,2013,19(6):1363-1374.
13 Darb-Esfahani S,Kunze CA,Kulbe H,et al.Prognostic impact of programmed cell death-1(PD-1)and PD-ligand 1(PD-L1)expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma[J].Oncotarget,2016,7(2):1486-1499.
14 Shaheen S,Mirshahidi H,Nagaraj G,et al.Conservative management of nivolumab-induced pericardial effusion:a case report and review of literature[J].Exp Hematol Oncol,2018,7(11):1-5.
15 Hamanishi J,Mandai M,Ikeda T,et al.Safety and antitumor activity of anti-PD-1 antibody,Nivolumab,in patients with platinum-resistant ovarian cancer[J].J Clin Oncol,2015,33(34):4015-4022.
16 Zorn KK,Bonome T,Gangi L,et al.Gene expression profiles of serous,endometrioid,and clear cell subtypes of ovarian and endometrial cancer[J].Clin Cancer Res,2005,11(18):6422-6430.
17 Inayama Y,Hamanishi J,Matsumura N,et al.Antitumor effect of Nivolumab on subsequent chemotherapy for platinum-resistant ovarian cancer oncologist[J].Oncologist,2018,23(11):1382-1384.
18 Normann MC,Türzer M,Diep LM,et al.Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer[J].J Gynecol Oncol,2019,30(4):e56.
19 Boyiadzis MM,Kirkwood JM,Marshall JL,et al.Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease[J].J Immunother Cancer,2018,6(35):1-7.
20 Varga A,Piha-Paul S,Ott PA,et al.Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer:analysis of KEYNOTE-028[J].Gynecol Oncol,2019,152(2):243-250.
21 Matulonis UA,Shapira-Frommer R,Santin AD,et al.Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer:results from the phase 2 KEYNOTE-100 study[J].Ann Oncol,2019,30(7):1080-1087.
22 Herbst RS,Soria JC,Kowanetz M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature,2014,515(7528):563-567.
23 Infante JR,Braiteh F,Emens LA,et al.Safety,clinical activity and biomarkers of atezolizumab(atezo)in advanced ovarian cancer(OC)[J].Ann Oncol,2016,27(6):296-312.
24 Liu JF,Gordon M,Veneris J,et al.Safety,clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers[J].Gynecol Oncol,2019,154(2):314-322.
25 Heery CR,Sullivan Coyne GH,Madan RA,et al.Phase I open-label,multiple ascending dose trial of MSB0010718C,an anti-PD-L1 monoclonal antibody,in advanced solid malignancies[J].J Clin Oncol,2014,32(15):3064.
26 Boyerinas B,Jochems C,Fantini M,et al.Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab(MSB0010718C)on human tumor cells[J].Cancer Immunol Res,2015,3(10):1148-1157.
27 Disis ML,Taylor MH,Kelly K,et al.Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer:phase 1b results from the JAVELIN solid tumor trial[J].JAMA Oncol,2019,5(3):393-401.
28 Zhang L,Chen Y,Li F,et al.Atezolizumab and bevacizumab Attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing epithelial-mesenchymal transition[J].Front Immunol,2019,10:867.
29 Liu JF,Herold C,Gray KP,et al.Assessment of combined Nivolumab and bevacizumab in relapsed ovarian cancer:A phase 2 clinical trial[J].JAMA Oncol,2019[Epub ahead of print].
30 Konstantinopoulos PA,Waggoner S,Vidal GA,et al.Single-arm phases 1 and 2 trial of Niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J].JAMA Oncol,2019[Epub ahead of print].
31 Drew Y,De Jonge M,Hong SH,et al.An open-label,phase II basket study of olaparib and durvalumab(MEDIOLA):Results in germline BRCA-mutated(gBRCAm)platinum sensitive relapsed(PSR)ovarian cancer(OC)[J].Gynecol Oncol,2018,149:246-247.
32 Lee JM,Cimino-Mathews A,Peer CJ,et al.Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly(ADP-ribose)polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in Women′s cancers:a dose-escalation,phase I study[J].J Clin Oncol,2017,35(19):2193-2202.
33 Topalian SL,Sznol M,McDermott DF,et al.Survival,durable tumor remission,and long-term safety in patients with advanced melanoma receiving nivolumab[J].J Clin Oncol,2014,32(10):1020-1030.

[1]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[2]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[3]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[4]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.
[5]	邓明新, 张颖. 环状RNA与卵巢癌研究新进展[J]. 实用肿瘤学杂志, 2019, 33(6): 549-552.
[6]	张慧婷, 娄阁. 卵巢癌肿瘤微环境的三维细胞培养模型研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 557-560.
[7]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[8]	宋玲, 付琼. 紫云英苷通过上调PHD2抑制缺氧诱导的卵巢癌细胞增殖和侵袭[J]. 实用肿瘤学杂志, 2019, 33(5): 407-414.
[9]	张蓓蕾, 李怡, 吴涛, 姜锋, 赵宏喜, 李艳红. 血根碱通过诱导细胞凋亡抑制卵巢癌肿瘤生长的机制研究[J]. 实用肿瘤学杂志, 2019, 33(4): 305-309.
[10]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.
[11]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.
[12]	宋玲, 付琼. 紫云英苷通过抑制HIF-1α诱导的糖酵解途径发挥抗卵巢肿细胞作用的研究[J]. 实用肿瘤学杂志, 2018, 32(6): 503-509.
[13]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[14]	梁冠盈, 迟秋君, 李晓梅. 伏立诺他对卵巢癌SKOV3细胞增殖和凋亡的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(4): 298-302.
[15]	孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.